Bizarre Patents
System for magnetically attaching templeless eyewear to a person
A system of eyewear that eliminates the need for hinges on the frames of the eyewear.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7329411 | Ophthalmic compositions containing a synergistic combination of three polymers Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity. ... | 02/12/2008 |
| 7307096 | Combined agents for treatment of glaucoma A pharmaceutical composition for the prophylaxis or treatment of glaucoma which comprises an angiotensin II antagonist and at least one compound selected from an adrenaline receptor blocker, a prostaglandin and a carbonic anhydrase inhibitor; and a method for the pr... | 12/11/2007 |
| 7244440 | Ophthalmic compositions containing a synergistic combination of three polymers Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity. ... | 07/17/2007 |
| 7220780 | Naaladase inhibitors for treating retinal disorders and glaucoma The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors. ... | 05/22/2007 |
| RE39609 | 8-iso-prostaglandins for glaucoma therapy The present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma It is based, at least in part, on the discovery that 8-iso prostaglandin E2 effectively de... | 05/01/2007 |
| 7129257 | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma Pyrazolo[3,4-e]benzoxazoles and analogues thereof for lowering intraocular pressure and treating glaucoma are disclosed. ... | 10/31/2006 |
| 7084128 | Method for reducing intraocular pressure The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a purinerginic receptor ligand, which is a mononucleoside polyphosphate or ... | 08/01/2006 |
| 7005446 | Use of AP-1 activators to treat glaucoma and ocular hypertension Compositions comprising AP-1 activators and methods of use for treating glaucoma and ocular hypertension are disclosed. ... | 02/28/2006 |
| 6960300 | Process for preparing water soluble diterpenes and their applications Aqueous solutions of diterpenes such as Forskolin, its congeners, analogs and derivatives, up to approximately 6% concentration, are prepared using suitably substituted cyclodextrin as a solubilizing agents. In the absence of cyclodextrin, some diterpenes such as Fo... | 11/01/2005 |
| 6956057 | EP4 agonists as agents for lowering intraocular pressure The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound which is a EP4 agonist. ... | 10/18/2005 |
| 6927233 | 5ht2 agonists for controlling IOP and treating glaucoma Compositions and methods for controlling intraocular pressure and treating glaucoma using 1-(2-aminopropyl)-indazol-6-ol are disclosed. ... | 08/09/2005 |
| 6855690 | Methods and compositions for treating ocular disorders The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a h... | 02/15/2005 |
| 6770675 | Compositions and methods for reducing ocular hypertension An improved ophthalmic composition, including docosanoid active agents, which is especially useful in lowering intraocular pressure associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concentrations are achiev... | 08/03/2004 |
| 6750196 | Methods of treating disorders of the eye In general, the present invention provides methods for promoting the function of retinal cells using neuregulins. A novel aspect of the invention involves the use of neuregulins as growth factors tp promote survival of retinal cells. Treating of the retinal cells to... | 06/15/2004 |
| 6723748 | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension Disclosed is the use of cloprostenol and fluprostenol analogues in combination with carbonic anhydrase inhibitors for the treatment of glaucoma and ocular hypertension and ophthalmic compositions therefor. ... | 04/20/2004 |
| 6716830 | Ophthalmic antibiotic compositions containing moxifloxacin Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal cond... | 04/06/2004 |
| 6673812 | Preventives/remedies for glaucoma An agent for the prophylaxis and treatment of glaucoma, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of glaucoma, which contains a compound of the formula (I) ##STR1## wher... | 01/06/2004 |
| 6664286 | Serotonergic 5ht2 agonists for treating glaucoma Compounds with 5HT2 receptor agonist activity useful for treating glaucoma, including lowering intraocular pressure. Compositions and methods for their use are also disclosed.... | 12/16/2003 |
| 6649195 | Eyesight enhanced maintenance composition A powerful formulation for preventing and treating macular degeneration, cataracts, glaucoma and other eye diseases, and contains over thirty naturally effective vitamins, minerals, phytonutrients and amino acids, which have all been found to demonstrate ... | 11/18/2003 |
| 6646001 | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension Disclosed are methods and compositions for the treatment of glaucoma and ocular hypertension, comprising the administration of a prostaglandin FP receptor agonist and a prostaglandin synthesis inhibitor.... | 11/11/2003 |
| 6627603 | Method for releasing an active principle contained a multiple emulsion A method for the controlled release of an active principle contained in a multiple water-in-oil-in-water emulsion characterized in that the multiple emulsion comprises an invert emulsion Ei with an aqueous phase A1 containing at least a hydrophilic active... | 09/30/2003 |
| 6555582 | Eye treatments using synthetic thyroid hormone compositions The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydrauli... | 04/29/2003 |
| 6548535 | Method for treating ocular hypertension This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of ... | 04/15/2003 |
| 6545045 | Prostaglandin E agonists for treatment of glaucoma This application relates to compositions and methods for the treatment of glaucoma and/or ocular hypertension in mammals utilizing prostaglandin E receptor agonists.... | 04/08/2003 |
| 6545036 | Ophthalmic compositions for treating ocular hypertension This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use... | 04/08/2003 |
| 6534475 | Use of TIMP-3 inducers of TIMP-3 expression, and TIMP-3 mimetics to treat ocular neovascularization Methods and compositions for treating ocular neovascularization with TIMP-3, TIMP-3 inducers, and TIMP-3 mimetics are disclosed.... | 03/18/2003 |
| 6528516 | Methods for reducing intraocular pressure using A3 adenosine receptor antagonists This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen.... | 03/04/2003 |
| 6511660 | Ophthalmic drug delivery formulations and method for preparing the same The present invention provides novel ophthalmic drug delivery formulation which comprises a mixture of Carbopol and Pluronic. Carbopol is a trademark of B.F. Goodrich Company's high molecular weight carboxy vinyl polymers (MW above 1,000,000). Pluronic be... | 01/28/2003 |
| 6509332 | Methods of treating excessive intraocular pressure This invention comprises methods of treatment, prevention, inhibition or alleviation of the problems associated with excessive intraocular pressure comprising administration of a compound of the formulae I or II: ##STR1## wherein Z is a moiety selected fr... | 01/21/2003 |
| 6500831 | Non-peptide bradykinin receptor antagonists for use in controlling intraocular pressure and treating glaucoma This invention relates to the topical ocular use of non-peptide bradykinin receptor antagonists to treat glaucoma and ocular hypertension.... | 12/31/2002 |
| 6458376 | Nonaqueous fluorinated drug delivery suspensions Nonaqueous pharmaceutical compositions for use in aqueous physiological systems are disclosed comprising drug delivery suspension of nonaqueous perfluorocarbon or fluorinated silicone liquid carriers. The suspended drug may be water labile or water stable... | 10/01/2002 |
| 6458836 | Treatment of ocular hypertension and glaucoma Disclosed is treatment of ocular hypertension and glaucoma by long-term therapy with a prostaglandin related compound for eliminating or reducing potential iridic pigmentation. Composition useful for the treatment, and use of the prostaglandin related com... | 10/01/2002 |
| 6455590 | Deprenyl compounds for treatment of glaucoma Methods and kits for treament of glaucoma are disclosed. In general, the methods of the invention include administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.... | 09/24/2002 |
| 6451799 | Drugs for ameliorating ocular circulatory disorders An agent for ameliorating ocular circulatory disorder containing a 1,4-dihydropyridine derivative of the formula (I) ##STR1## wherein each symbol is as defined in the specification, or an acid addition salt thereof as an active ingredient. The agent for a... | 09/17/2002 |
| 6444676 | Use of PARP inhibitors in the treatment of glaucoma The invention provides pharmaceutical compositions containing PARP inhibitors and methods of using these compositions to prevent, treat or ameliorate glaucomatous retinopathy and/or optic neuropathy.... | 09/03/2002 |
| 6441047 | Combination therapy for treating glaucoma Methods for treating persons with glaucoma or ocular hypertension with glutamate antagonists and IOP-lowering compounds are disclosed.... | 08/27/2002 |
| 6426358 | Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma A method and composition for altering a plausible sequence of pathological events in retinal ganglion cells associated with glaucoma, the sequence including membrane depolarization, influx of millimolar amounts of Na+ via non-inactivating Na | 07/30/2002 |
| 6423321 | Cytokine antagonists for the treatment of sensorineural hearing loss Specific Cytokine Antagonists, including TNF antagonists and/or Interleukin-1 antagonists, are used as novel therapeutic agents for the treatment of hearing loss, including presbycusis and other forms of sensorineural hearing loss. The present invention p... | 07/23/2002 |
| 6419944 | Cytokine antagonists for the treatment of localized disorders Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a her... | 07/16/2002 |
| 6414021 | Control of intraocular pressure during surgery An ocular infusion solution containing a prostaglandin-like compound or prostaglandin-analog is used during ocular surgery for maintaining desired intraocular pressure of the patient.... | 07/02/2002 |
